Phase II study to evaluate the efficacy and tolerability of fulvestrant 250mg, 250mg plus 500mg loading regimen and 500mg in postmenopausal women with ER +ve advanced breast cancer progressing or relapsing after previous endocrine therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms FINDER-II
- Sponsors AstraZeneca
- 09 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2018.
- 29 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 16 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.